A Single Dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of MK5478 in Subjects and in Patients With Hypertension
Phase of Trial: Phase I
Latest Information Update: 15 Jun 2017
At a glance
- Drugs MK 5478 (Primary) ; Candesartan cilexetil
- Indications Hypertension
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 13 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Sep 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 12 Jan 2010 New trial record